Published in Antimicrob Agents Chemother on February 01, 1980
In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother (1982) 21.31
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother (1985) 11.34
Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae. Antimicrob Agents Chemother (1981) 11.11
In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother (1982) 10.08
Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1984) 8.62
Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections. Antimicrob Agents Chemother (1981) 8.59
In vitro antibacterial activity of norfloxacin (MK-0366). Antimicrob Agents Chemother (1982) 6.97
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother (1986) 6.03
Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother (1986) 6.00
Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes. Antimicrob Agents Chemother (1982) 5.67
In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother (1982) 5.54
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid. Antimicrob Agents Chemother (1983) 5.45
In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother (1983) 5.21
Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 4.96
In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother (1989) 4.38
In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives. Antimicrob Agents Chemother (1984) 4.22
In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother (1988) 4.03
In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound. Antimicrob Agents Chemother (1983) 4.00
Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates. Antimicrob Agents Chemother (1982) 3.99
In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother (1992) 3.88
In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother (1987) 3.84
In vitro and in vivo antibacterial activity of AT-2266. Antimicrob Agents Chemother (1983) 3.80
Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli. Antimicrob Agents Chemother (1986) 3.69
In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother (1988) 3.52
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative. Antimicrob Agents Chemother (1986) 3.38
Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography. Antimicrob Agents Chemother (1982) 3.24
Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant. J Bacteriol (1987) 3.04
Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother (1985) 2.71
In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens. Antimicrob Agents Chemother (1983) 2.70
In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother (1993) 2.61
Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. Antimicrob Agents Chemother (1983) 2.58
Activities of new quinoline derivatives against genital pathogens. Antimicrob Agents Chemother (1985) 2.51
Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1989) 2.36
In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother (1992) 2.32
In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother (1993) 2.18
Antibacterial activity of norfloxacin. Antimicrob Agents Chemother (1983) 2.15
In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob Agents Chemother (1986) 2.02
Effects of norfloxacin on DNA metabolism in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1986) 1.97
In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother (1994) 1.96
Purification of Citrobacter freundii DNA gyrase and inhibition by quinolones. Antimicrob Agents Chemother (1988) 1.93
Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice. Antimicrob Agents Chemother (1983) 1.90
Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin. Antimicrob Agents Chemother (1988) 1.88
Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715). Antimicrob Agents Chemother (1983) 1.83
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob Agents Chemother (1986) 1.81
Susceptibility of Campylobacter species to nalidixic acid, enoxacin, and other DNA gyrase inhibitors. Antimicrob Agents Chemother (1985) 1.61
DNA gyrase of Staphylococcus aureus and inhibitory effect of quinolones on its activity. Antimicrob Agents Chemother (1988) 1.60
Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans. Antimicrob Agents Chemother (1983) 1.59
Comparative in vitro antibacterial activity of sparfloxacin (AT-4140; RP 64206), a new quinolone. Antimicrob Agents Chemother (1991) 1.42
Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats. Antimicrob Agents Chemother (1988) 1.37
Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother (1989) 1.34
In vitro antibacterial activity of a new quinolone, NM394. Antimicrob Agents Chemother (1991) 1.25
In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative. Antimicrob Agents Chemother (1989) 1.11
Multiclinic comparative study of norfloxacin and trimethoprim-sulfamethoxazole for treatment of urinary tract infections. Antimicrob Agents Chemother (1985) 1.08
In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin). Antimicrob Agents Chemother (1985) 1.07
Antibacterial activity of ofloxacin and its mode of action. Infection (1986) 1.01
In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent. Antimicrob Agents Chemother (1993) 1.00
Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria. Antimicrob Agents Chemother (1992) 0.97
In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone. Antimicrob Agents Chemother (1996) 0.93
Comparative activities of eight quinolones against members of the Bacteroides fragilis group. Antimicrob Agents Chemother (1994) 0.91
Efficacy of NY-198 against experimental Legionnaires disease. Antimicrob Agents Chemother (1988) 0.88
Modulation of cell wall synthesis by DNA replication in Escherichia coli during initiation of cell growth. J Bacteriol (1987) 0.86
In vitro and in vivo antibacterial activities of KB-5246, a new tetracyclic quinolone. Antimicrob Agents Chemother (1989) 0.85
Lytic effect of two fluoroquinolones, ofloxacin and pefloxacin, on Escherichia coli W7 and its consequences on peptidoglycan composition. Antimicrob Agents Chemother (1991) 0.84
Antibacterial activity of norfloxacin in the gastrointestinal tracts of rats. Antimicrob Agents Chemother (1983) 0.78
Norfloxacin and silver norfloxacin in the treatment of Pseudomonas corneal ulcer in the rabbit. Trans Am Ophthalmol Soc (1984) 0.78
Norfloxacin penetration into subcutaneous tissue cage fluid in rabbits and efficacy in vivo. Antimicrob Agents Chemother (1983) 0.78
A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone. Curr Med Chem (2016) 0.75
The place of temocillin in the treatment of hospital infections. Drugs (1985) 0.75
1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS. J Med Pharm Chem (1962) 13.97
Pyrido(2,3-d)pyrimidine antibacterial agents. 3. 8-Alkyl- and 8-vinyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)pyrido(2,3-d)pyrimidine-6-carboxylic acids and their derivatives. J Med Chem (1975) 8.52
Pipemidic acid: its activities against various experimental infections. Antimicrob Agents Chemother (1976) 7.92
Changing ecology of bacterial infections as related to antibacterial therapy. J Infect Dis (1970) 7.72
Effect of inoculum and of beta-lactamase on the anti-staphylococcal activity of thirteen penicillins and cephalosporins. Antimicrob Agents Chemother (1975) 6.82
Nalidixic acid and oxolinic acid in the treatment of chronic bacteriuria. Ann Intern Med (1969) 4.41
Studies on quinoline derivatives and related compounds. 5. Synthesis and antimicrobial activity of novel 1-alkoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. J Med Chem (1977) 4.19
Changing patterns in surgical infections. Ann Surg (1973) 3.88
Antibacterial activity of apalcillin (PC-904) against gram-negative bacilli, especially ampicillin-, carbenicillin-, and gentamicin-resistant clinical isolates. Antimicrob Agents Chemother (1978) 3.65
Determination of the ID50 values of antibacterial agents in agar. J Antibiot (Tokyo) (1978) 3.08
In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother (1982) 21.31
Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections. Antimicrob Agents Chemother (1981) 8.59
Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection (1984) 7.53
In vitro and in vivo antibacterial activity of T-1220, a new semisynthetic penicillin. Antimicrob Agents Chemother (1977) 7.35
Purification and properties of inducible penicillin beta-lactamase isolated from Pseudomonas maltophilia. Antimicrob Agents Chemother (1982) 7.11
Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1991) 7.10
CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet (1994) 7.07
Molecular cloning of the gene of a penicillin-binding protein supposed to cause high resistance to beta-lactam antibiotics in Staphylococcus aureus. J Bacteriol (1986) 6.97
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell (1994) 6.45
Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli. Antimicrob Agents Chemother (1986) 6.03
Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12. Antimicrob Agents Chemother (1986) 6.00
The purification and properties of penicillin beta-lactamases mediated by transmissible R factors in Escherichia coli. J Biochem (1969) 5.35
Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 4.96
Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol (2001) 4.80
Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique. Circulation (1983) 4.70
In vitro antibacterial activity of cefoperazone (T-1551), a new semisynthetic cephalosporin. Antimicrob Agents Chemother (1979) 4.49
In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother (1989) 4.38
Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J Med Chem (1980) 4.12
Purification and properties of a new beta-lactamase from Pseudomonas cepacia. Antimicrob Agents Chemother (1980) 4.09
In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother (1987) 3.84
Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan. Antimicrob Agents Chemother (1996) 3.82
In vitro and in vivo antibacterial activity of AT-2266. Antimicrob Agents Chemother (1983) 3.80
New norfloxacin resistance gene in Pseudomonas aeruginosa PAO. Antimicrob Agents Chemother (1990) 3.71
Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli. Antimicrob Agents Chemother (1986) 3.69
Antibacterial activity of apalcillin (PC-904) against gram-negative bacilli, especially ampicillin-, carbenicillin-, and gentamicin-resistant clinical isolates. Antimicrob Agents Chemother (1978) 3.65
Plasma (1-->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet (1995) 3.64
Biochemical properties of beta-lactamase produced by Flavobacterium odoratum. Antimicrob Agents Chemother (1985) 3.62
Properties of novel beta-lactamase produced by Bacteroides fragilis. Antimicrob Agents Chemother (1983) 3.59
In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother (1988) 3.52
Induction of beta-lactamase by various beta-lactam antibiotics in Enterobacter cloacae. Antimicrob Agents Chemother (1980) 3.48
The decline in child mortality: a reappraisal. Bull World Health Organ (2000) 3.46
Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother (1998) 3.41
Plasmid-mediated penicillin beta-lactamases in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1976) 3.40
In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative. Antimicrob Agents Chemother (1986) 3.38
Variant of penicillinase mediated by an R factor in Escherichia coli. J Bacteriol (1970) 3.33
Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature (2001) 3.24
In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrob Agents Chemother (1987) 3.12
Determination of the ID50 values of antibacterial agents in agar. J Antibiot (Tokyo) (1978) 3.08
Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873. Antimicrob Agents Chemother (1984) 3.07
Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res (1993) 3.05
Drug resistance of enteric bacteria. XIV. Comparison of beta-lactamases in gram-negative rod bacteria resistant to alpha-aminobenzylpenicillin. Jpn J Microbiol (1968) 3.04
Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant. J Bacteriol (1987) 3.04
Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. J Biol Chem (1977) 3.02
Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration. J Biol Stand (1974) 3.02
Human thyroid peroxidase: complete cDNA and protein sequence, chromosome mapping, and identification of two alternately spliced mRNAs. Proc Natl Acad Sci U S A (1987) 3.00
In vitro and in vivo antibacterial activity of AB206, a new naphthyridine derivative. Antimicrob Agents Chemother (1980) 2.98
Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene (1990) 2.97
Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure. J Am Coll Cardiol (1994) 2.89
An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat Genet (1996) 2.89
Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother (1985) 2.87
RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci (1999) 2.86
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1996) 2.84
Activity of beta-lactamase produced by Bacteroides fragilis against newly introduced cephalosporins. Antimicrob Agents Chemother (1980) 2.76
Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res (1999) 2.74
Beta-lactamase stability and antibacterial activity of cefmenoxime (SCE-1365), a novel cephalosporin. Antimicrob Agents Chemother (1981) 2.72
Distribution of hepatic sulfite oxidase among subcellular organelles and its intraorganelle localization. J Biochem (1977) 2.71
Biochemical properties of a penicillin beta-lactamase mediated by R factor from Bordetella bronchiseptica. Antimicrob Agents Chemother (1975) 2.70
STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci U S A (1996) 2.64
Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections. Infect Immun (1984) 2.59
Comparative studies of penicillin-binding proteins in Pseudomonas aeruginosa and Escherichia coli. Eur J Biochem (1979) 2.58
Ischemic preconditioning increases adenosine release and 5'-nucleotidase activity during myocardial ischemia and reperfusion in dogs. Implications for myocardial salvage. Circulation (1993) 2.56
Phosphorylative inactivation of aminoglycosidic antibiotics by Escherichia coli carrying R factor. Science (1967) 2.55
Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res (2000) 2.54
Effect of N-formimidoyl thienamycin (MK0787) on beta-lactamases and activity against beta-lactamase-producing strains. Antimicrob Agents Chemother (1980) 2.53